结合一个共同的抑制剂的细菌和人类糖酶转移酶的结构为选择性治疗提供了信息
Beebee Yusrah Kaudeer1, Jacob M Kirsh1, Katsuhiko Mitachi2
1Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.
bioRxiv : the preprint server for biology
|December 25, 2025
概括
研究人员研究了MraY和DPAGT1酶,这些酶对细菌和人类细胞过程至关重要. 他们使用冷EM可视化一种抑制剂APPB,揭示了开发新抗菌和抗癌药物的见解.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 药物发现 药物发现 药物发现
背景情况:
- 葡萄糖合物对生物功能至关重要,由葡萄糖转移酶合成.
- MraY和DPAGT1分别是细菌peptidoglycan和真核生物N链 glycans 所必不可少的正体糖酶.
- 这些酶是开发抗菌和抗癌疗法的关键标.
研究的目的:
- 引导下一代小分子抑制剂的开发,以MraY和DPAGT1.1为目标.
- 阐明通过APPB (aminouridyl phenoxypiperidinbenzyl butanamide) 的抑制的结构基础.
- 为选择性MraY或DPAGT1特异性治疗提供设计原则.
主要方法:
- 单粒子冷电子显微镜 (cryo-EM) 用于确定与MraY和DPAGT1.1结合的APPB的结构.
- 在2.9 Å分辨率下对酶抑制剂复合物的分析.
- 对受抑制剂结合的骨科医生进行比较结构分析.
主要成果:
- 透露了冷电磁结构 APPB在MraY和DPAGT1.1中采用了两个不同的形状.
- 符合性选择与中央胺碳基的局部结相互作用相关.
- 结构洞察力为优化 DPAGT1 向抗癌剂和 MraY 向抗菌剂的 APPB 策略提供信息.
结论:
- 该研究为开发MraY和DPAGT1特异性抑制剂提供了关键的设计原则.
- 同时对受抑制剂结合的骨干学家进行结构性表征对于设计选择性疗法非常有价值.
- 这些发现支持基于APPB架构的新型抗菌和抗癌药物的开发.
相关概念视频
Enzyme Inhibition
91.1K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.1K
Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Protein Kinases and Phosphatases
14.8K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.8K
Phosphoinositides and PIPs
10.0K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.0K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
879
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
879


